Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group

Abstract

This study is the first to describe a population PK model of temsirolimus combined with sirolimus formation and disposition in paediatric patients. The developed model will facilitate PK model-based dose individualization of temsirolimus and the design of future clinical studies in children.

Targeting Aggrephagy for the Treatment of Alzheimer’s Disease

“…Rapamycin treatment in AD mice has alleviated Aβ burden, improved memory dysfunction, and rescued cerebral amyloid angiopathy [144,146]. Rapamycin, as well as its prodrug form Temsirolimus [147] shows potent AD therapeutic effect in reducing p-Tau aggregates in P301S mice [148,149]. Polyphenol curcumin is a potent PI3K and mTOR inhibitor reported to alleviate AD pathology.…”

Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real‑world data

“…The present study was a retrospective study and was approved by the ethics committee of this hospital without the requirement for written informed consent. A previous study have used lower patient numbers (15).…”

Critical Considerations in Anticancer Drug Development and Dosing Strategies: The Past, Present, and Future

“…However, there have been several attempts to implement Bayesian pharmacokinetic dose adjustments in the treatment of cancer, focusing initially on model development, with planned implementation for dose adjustments in patients. 116 In a recent editorial of the application of new technologies to medicine, Vinks 117 45 These heuristics often play a substantial role whenever there is uncertainty in a decision-making process, but can result in biases that are not supported by observations. average of 17 years for new knowledge generated by randomized controlled trials to be incorporated into practice, and even then application is highly uneven."…”

“…However, there have been several attempts to implement Bayesian pharmacokinetic dose adjustments in the treatment of cancer, focusing initially on model development, with planned implementation for dose adjustments in patients. 116 In a recent editorial of the application of new technologies to medicine, Vinks 117 quoted a 2001 report from the Institute of Medicine that concluded: "Scientific knowledge about best care is not applied systematically or expeditiously to clinical practice. It now takes an S124 The Journal of Clinical Pharmacology / Vol 57 No S10 2017 45 These heuristics often play a substantial role whenever there is uncertainty in a decision-making process, but can result in biases that are not supported by observations.…”

“…To facilitate the application of Bayesian forecasting to individualize anticancer therapy, a dosing system for methotrexate in children that linked to NONMEM was developed by Barrett et al and retrospectively was shown to have good predictive performance, although it saw little practical use. However, there have been several attempts to implement Bayesian pharmacokinetic dose adjustments in the treatment of cancer, focusing initially on model development, with planned implementation for dose adjustments in patients . In a recent editorial of the application of new technologies to medicine, Vinks quoted a 2001 report from the Institute of Medicine that concluded: “Scientific knowledge about best care is not applied systematically or expeditiously to clinical practice.…”